Experimental cancer combo study halted early
Disease control
Terminated
This study tested a new drug called OC-001, given alone or with an immunotherapy drug (Avelumab), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The study was stopped early and involved 73 participants with v…
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated May 17, 2026 02:01 UTC